ProQR公布Ax-0810一期临床试验积极安全性及药代动力学数据,确定开发候选药物并展望2026年

美股速递
Jan 08

生物技术公司ProQR Therapeutics NV(NASDAQ: PRQR)近日披露了其研发管线的重要进展。公司宣布,针对Ax-0810的一期临床试验获得了令人鼓舞的安全性和药代动力学(PK)数据,初步结果显示该药物在受试者中耐受性良好,药代动力学特征符合预期,为后续临床开发奠定了坚实基础。

与此同时,ProQR已正式确定Ax-0810作为重点开发候选药物,将加快推进其后续临床研究计划。公司还同步更新了其研发战略与远期规划,明确了至2026年的发展目标与预期里程碑,展现出对创新疗法持续投入的决心与清晰路径。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10